{"analyses":[{"ciLowerLimit":"0.55","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.76","estimateComment":"Stratified Cox Proportional Hazards model. A hazard ratio \\< 1 favours Dato-DXd.","groupDescription":"Dato-DXd versus ICC","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.64","statisticalComment":"Adjusted for the stratification factors","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.9","upperLimit":"7.2","value":"6.9"},{"groupId":"OG001","lowerLimit":"4.2","upperLimit":"5.5","value":"4.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"365"},{"groupId":"OG001","value":"367"}],"units":"Participants"}],"description":"PFS by Investigator assessment will be defined as the time from the date of randomization until the date of PD per RECIST 1.1 (by Investigator assessment) or death (by any cause in the absence of progression), (ie, date of event or censoring - date of randomization + 1).","dispersionType":"95% Confidence Interval","groups":[{"description":"Arm 1: Dato-DXd","id":"OG000","title":"Dato-DXd"},{"description":"Arm 2: ICC (Capecitabine or Gemcitabine or Eribulin mesylate or Vinorelbine)","id":"OG001","title":"Investigator's Choice of Chemotherapy (ICC)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months","title":"Progression-Free Survival by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Months"}